Manages leukemia, lymphoma, and solid tumor malignancies. ANDA 76870, held by Hikma. Allopurinol Sodium.
As of Nov 16, 2026, ANDA 76870 (Allopurinol Sodium), held by Hikma, was first approved by FDA on Aug 26, 2004, with 3 approved supplements and 0 published complete response letters.
Allopurinol Sodium for Injection is indicated for the management of adult and pediatric patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 26, 2004 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Allopurinol SodiumEQ 500MG BASE/VIAL · injectable;injection | Allopurinol Sodium | Rx |
| Mar 13, 2026 | Supplement 10Manufacturing · Standard review | Approved | None posted |
| Mar 13, 2026 | Supplement 11Manufacturing · Standard review | Approved | None posted |
| Sep 9, 2016 | Supplement 9Manufacturing | Approved | None posted |
| Aug 26, 2004 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters